VANISH2: Ablation vs Drugs for VT

Phase 4, randomised, open-label trial in ventricular tachycardia (VT) (2 arms). Primary endpoints: Composite outcome of death at any time, appropriate ICD shock after 14 days, ventricular tachycardia storm after 14 days or treated sustained ventricular tachycardia below the detection rate of the…, All-cause mortality at 8 years and 3 more. Started Oct 2016; status: completed.